Latest Competition News

Racura Oncology has detailed how its lead drug candidate, (E,E)-bisantrene, silences the cancer-driving MYC gene by stabilising G-quadruplex DNA structures, providing critical preclinical validation ahead of ongoing clinical trials.

Airtasker Limited posted robust 3Q26 results highlighted by strong Australian marketplace momentum and explosive growth in the UK and US. The company reaffirmed its FY26 guidance, underpinned by strategic media partnerships and a solid cash position.

Global Lithium Resources has locked in a strategic A$7.32 million equity placement and a US$75 million offtake prepayment from Chinese battery materials giant Jiangsu Lopal Tech, accelerating development of its flagship Manna Lithium Project in Western Australia.

Praemium Limited lifted its total Funds Under Administration by 18% to $73.7 billion in Q3 FY26, driven by strong net inflows and growth in its non-custodial portfolio administration. The ongoing integration of Technotia is set to deliver $9 million in annual technology salary savings from FY27.

Noxopharm reports preclinical data revealing SOF-SKN’s active ingredient remains in skin tissues for about 3.5 days with minimal systemic absorption, supporting less frequent dosing and sustained activity for cutaneous lupus treatment.

Terramin Australia has advanced its flagship Tala Hamza Zinc Project into early development with strong Algerian government backing and a revised 2.0Mtpa mining study. Meanwhile, a court ruling returned the Bird in Hand Gold deposit to the company, prompting strategic reviews, all while the group manages a tight cash position supported by a recent $1 million share placement.

StepChange Holdings delivered a robust $15.18 million in unaudited revenue and $1.46 million EBITDA in Q3 2026, driven by organic growth and the BroadReach acquisition. Margin improvements and AI integration highlight its evolving consulting model.

Lindian Resources has locked in a US$11.6 million financing package from Malawi's NBS Bank, bolstering the Kangankunde Rare Earths Project with asset-backed and working capital facilities. This deal complements Lindian’s recent A$100 million placement and underscores its commitment to local partnerships.

Bank of Queensland’s statutory profit fell 20% to $136 million in 1H26, weighed down by a $31 million loss on its equipment finance portfolio sale. The bank advances its digital transformation and plans a $3.7 billion capital release with Challenger Limited, maintaining strong capital and dividend guidance.

Sunrise Energy Metals has confirmed strong economics for its Syerston Scandium Project with a US$120 million feasibility study, targeting 60 tonnes per year of scandium oxide and potential expansion to 180 tonnes. The project benefits from US government financing interest and rising global demand amid Chinese export restrictions.

Starpharma has secured FDA alignment on the clinical development plan for its DEP® HER2 radiotherapy candidate, paving the way for a first-in-human phase 1 study in advanced HER2-positive cancers scheduled for H2 2026.

Compumedics maintains robust sales momentum but faces FY26 revenue timing challenges due to MEG installation delays and a cautious Somfit D rollout. The company expects solid year-on-year growth and positions for improved execution in FY27.